y-based
research operation specializing in all phases of cancer clinical trials.
The research network currently has 595 physicians actively enrolling
patients, 109 research sites, and is currently involved in 63 open research
trials. The network has contributed to the development of 24 of 30 of the
latest cancer-fighting drugs approved by the Food and Drug Administration
for use. Since 1993, more than 32,000 patients have participated in
clinical trials managed by US Oncology network practices. For more
information, visit the "Research" section under "Our Services" on the
company's Web site,
http://www.usoncology.com.
About US Oncology, Inc.
US Oncology, headquartered in Houston, works closely with physicians,
manufacturers and payers to identify and deliver innovative services that
enhance patient access to advanced cancer care. US Oncology supports one of
the nation's foremost cancer treatment and research networks accelerating
the availability and use of evidence-based medicine and shared best
practices.
US Oncology's expertise in supporting every aspect of the cancer care
delivery system -- from drug development to treatment and outcomes
measurement, enables the company to help increase the efficiency and safety
of cancer care. According to the company's last quarterly earnings report,
US Oncology is affiliated with 1,247 physicians operating in 472 locations,
including 91 radiation oncology facilities in 39 states. For more
information, visit the company's Web site, http://www.usoncology.com.
'/>"/>SOURCE US Oncology, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois2.
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting3.
Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting4.
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting5.
About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO6.
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting7.
Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting8.
Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting9.
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology10.
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology11.
Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer